USANA Health Sciences, Inc. (NYSE:USNA – Get Rating) Director Gilbert A. Fuller sold 312 shares of the firm’s stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $68.25, for a total value of $21,294.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NYSE USNA traded down $0.66 during trading on Monday, reaching $68.68. 66,112 shares of the stock traded hands, compared to its average volume of 70,952. USANA Health Sciences, Inc. has a 52-week low of $67.82 and a 52-week high of $107.85. The stock has a market capitalization of $1.32 billion, a P/E ratio of 12.70 and a beta of 0.84. The company has a 50-day moving average of $77.56 and a 200-day moving average of $89.87.
USANA Health Sciences (NYSE:USNA – Get Rating) last posted its quarterly earnings data on Tuesday, April 26th. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. USANA Health Sciences had a return on equity of 27.04% and a net margin of 9.41%. The firm had revenue of $272.87 million during the quarter, compared to analysts’ expectations of $270.80 million. During the same period in the prior year, the business earned $1.45 EPS. Equities analysts anticipate that USANA Health Sciences, Inc. will post 5.28 earnings per share for the current year.
A number of equities analysts have recently issued reports on USNA shares. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 26th. TheStreet downgraded USANA Health Sciences from a “b” rating to a “c+” rating in a research report on Wednesday, February 9th. Zacks Investment Research upgraded USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 14th. Finally, DA Davidson lowered their price objective on USANA Health Sciences from $86.00 to $76.00 in a research report on Wednesday, April 27th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, USANA Health Sciences presently has a consensus rating of “Buy” and an average target price of $105.00.
About USANA Health Sciences (Get Rating)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.
- Get a free copy of the StockNews.com research report on USANA Health Sciences (USNA)
- Time to Ring the Register on Funko Stock
- Stock Market Downgrades Are Dragging The S&P 500 Lower
- Palo Alto Networks Bottoms But A Rebound May Not Be Coming
- Under Armor Stock is Getting Undervalued
- The Institutions Go Long Saia, Inc In Q2
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.